All In Biotech

Drug Trial Radar · NCT04458259

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF 07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

88

Actual

Start

Sep 24, 2020

Primary completion

Nov 15, 2024

Study completion Nov 15, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors

Conditions

  • Neoplasm Metastasis

Interventions

  • PF-07265807Drug

    Given 2 weeks on/1 week off

  • SasanlimabDrug

    Given SC Q3W

  • AxitinibDrug

    Dosed per package label starting with 5 mg PO BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1, 2, and 3: Number of participants with dose limiting toxicities (DLTs)Time frame: Baseline through day 21 or 42
  2. Parts 1, 2 and 3: Number of participants with treatment emergent adverse events (AEs)Time frame: Baseline through approximately 2 years
  3. Parts 1, 2, and 3: Number of participants with laboratory abnormalitiesTime frame: Baseline through approximately 2 years
  4. Part 4: Overall Response Rate (ORR)Time frame: Baseline through approximately 2 years
  5. Part 4, Cohort 4: Complete Response (CR)Time frame: Baseline through approximately 2 years

Locations

33 sites in 5 countries. Site status is shown where the registry gives one.

  • Henry Eye Clinic

    Fayetteville, Arkansas

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • Highlands Oncology Group

    Rogers, Arkansas

  • Highlands Oncology Group

    Springdale, Arkansas

  • UCI Chao Family Comprehensive Cancer Center

    Orange, California

  • Clinical & Translational Science Institute

    San Francisco, California

  • UCSF Helen Diller Family Comprehensive Cancer Center - Mission Hall

    San Francisco, California

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Rocky Mountain Lions Eye Institute (RMLEI)

    Aurora, Colorado

  • University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)

    Aurora, Colorado

  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)

    Aurora, Colorado

  • University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)

    Aurora, Colorado

  • Community Health Network, Inc.

    Indianapolis, Indiana

  • Community Health Network, Inc.

    Indianapolis, Indiana

  • Community Health Network Cancer Center North

    Indianapolis, Indiana

  • Community Health Network, Inc.

    Indianapolis, Indiana

  • Community Health Network, Inc.

    Indianapolis, Indiana

  • Brigham & Women's Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Dana-Farber Cancer Institute - Chestnut Hill

    Newton, Massachusetts

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • Duke Eye Center

    Durham, North Carolina

  • Duke University Medical Center, lnvestigational Chemotherapy Service

    Durham, North Carolina

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texas

  • University Health Network

    Toronto, Ontario, Canada

  • Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale

    Naples, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore

    Roma, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore

    Roma, ROME, Italy

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Fundacion Jimenez Díaz

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.